Lipid-based antifungal agents: a concise overview

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Mycology and Infectious Diseases

Background:

• Lipid formulations represent significant advancements in systemic antifungal therapy.
• Established lipid-based amphotericin B formulations include ABLC, ABCD, and L-AMB, used clinically since the 1990s.
• These formulations exhibit reduced nephrotoxicity compared to conventional amphotericin B, allowing for higher, safer doses.

Purpose of the Study:

• To provide a comprehensive overview of available data on lipid formulations of antifungal drugs.
• To summarize in vitro activity, pharmacokinetic profiles, in vivo efficacy, and safety data.
• To discuss emerging lipid-based polyene antifungals, such as liposomal nystatin.

Main Methods:

• Literature review and data synthesis.
• Analysis of in vitro studies, pharmacokinetic data, clinical efficacy, and safety profiles.
• Comparison of established lipid amphotericin B formulations and emerging liposomal nystatin.

Main Results:

• Lipid-based amphotericin B formulations demonstrate improved safety profiles, particularly reduced nephrotoxicity.
• High cost remains a significant barrier for these advanced formulations.
• Limited head-to-head comparative data exists for existing lipid amphotericin B formulations.

Conclusions:

• Lipid formulations of antifungal agents offer therapeutic advantages, primarily improved safety and tolerability.
• Further research and comparative studies are needed to fully elucidate the benefits and optimize the use of these agents.
• Liposomal nystatin represents a promising development in lipid-based polyene antifungal therapy.